AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8034522 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 429
Study 8034522 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 429
Study 2656860 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (11 patients) and 25 mg (1 patient) twice daily for 4 weeks
Number of subjects: 12
Study 2656860 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 12
Study 30946436 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation arm (arm 2)
Number of subjects: 516
Study 30946436 — intervention group
Group type: COMPARATOR
Intervention: Telerehabilitation with pharmacological pain management arm (arm 3)
Number of subjects: 516
Study 28255731 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (60 min of treadmill walking) in a post-absorptive state
Number of subjects: 12
Study 28255731 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (60 min of treadmill walking) in a postprandial state
Number of subjects: 12
Study 28255731 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no exercise)
Number of subjects: 12
Study 25483215 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 2397
Study 25483215 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 2397
Study 24055199 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual perspective-taking task during functional magnetic resonance imaging
Number of subjects: 20
Study 21498786 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 18
Study 21498786 — intervention group
Group type: EXPERIMENTAL
Intervention: Detemir
Number of subjects: 18
Study 21498786 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH
Number of subjects: 18
Study 19750263 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra parenteral fluid therapy (group I)
Number of subjects: 100
Study 19750263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 100
Study 16989902 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable telescope (IMT)
Number of subjects: 217
Study 16989902 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye controls
Number of subjects: 217
Study 12974172 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 11126933 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal text or RSVP text (coherent or scrambled)
Number of subjects: 0
Study 11126933 — intervention group
Group type: EXPERIMENTAL
Intervention: Words presented in text
Number of subjects: 0
Study 11126933 — intervention group
Group type: EXPERIMENTAL
Intervention: Study list words presented in RSVP
Number of subjects: 0
Study 11126933 — intervention group
Group type: COMPARATOR
Intervention: Words read aloud in a list
Number of subjects: 0
Study 9307346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin (2-g dose every 6 hours) and erythromycin (250-mg dose every 6 hours) for 48 hours followed by oral amoxicillin (250-mg dose every 8 hours) and erythromycin base (333-mg dose every 8 hours) for 5 days
Number of subjects: 614
Study 9307346 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo regimen
Number of subjects: 614
Study 9307346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ampicillin and erythromycin
Number of subjects: 614
Study 9307346 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo regimen in GBS-negative cohort
Number of subjects: 614
Study 8103875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (SK) 1.5 MU
Number of subjects: 4534
Study 8103875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4534
Study 3734034 — intervention group
Group type: COMPARATOR
Intervention: RU 486 (400 mg acute administration)
Number of subjects: 7
Study 3734034 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (400 mg daily for 3 days)
Number of subjects: 7
Study 3734034 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (in two patients with nonpituitary-dependent Cushing's syndrome)
Number of subjects: 7
Study 31667859 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational skills intervention / Homework completion intervention
Number of subjects: 274
Study 28695791 — intervention group
Group type: EXPERIMENTAL
Intervention: L+Z supplementation (12 mg/daily)
Number of subjects: 44
Study 28695791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 27775995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative alerts for double-low events
Number of subjects: 19292
Study 27775995 — intervention group
Group type: COMPARATOR
Intervention: No alerts (Control)
Number of subjects: 19292
Study 27775995 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative double-low time > 60 min
Number of subjects: 19292
Study 27775995 — intervention group
Group type: EXPERIMENTAL
Intervention: Median number of double-low minutes
Number of subjects: 19292
Study 24635053 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-ounce water swallowing test
Number of subjects: 47
Study 24635053 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing function questionnaire
Number of subjects: 47
Study 22507791 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone)
Number of subjects: 0
Study 22507791 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ACVBP
Number of subjects: 0
Study 22507791 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 0
Study 22507791 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ICE or R-DHAP followed by different conditioning regimens prior to ASCT
Number of subjects: 0
Study 22507791 — intervention group
Group type: EXPERIMENTAL
Intervention: New agents targeting different pathways such as lenalidomide
Number of subjects: 0
Study 22507791 — intervention group
Group type: EXPERIMENTAL
Intervention: New monoclonal antibodies
Number of subjects: 0
Study 22507791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruton’s tyrosine kinase inhibitor
Number of subjects: 0
Study 22507791 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 0
Study 20702739 — intervention group
Group type: EXPERIMENTAL
Intervention: Opponent-channel model response to outward ITD change
Number of subjects: 0
Study 20702739 — intervention group
Group type: COMPARATOR
Intervention: Topographic model response to inward ITD change
Number of subjects: 0
Study 18700639 — intervention group
Group type: EXPERIMENTAL
Intervention: Self care manual educational intervention
Number of subjects: 523
Study 18700639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to self care manual)
Number of subjects: 523
Study 15967223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of endothelin-1 (ET-1) in patients with SAH
Number of subjects: 30
Study 15967223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) levels of ET-1 in patients with different groups of the Hunt-Hess scale
Number of subjects: 30
Study 15967223 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of ET-1 in patients with SAH
Number of subjects: 30
Study 15967223 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study 12809395 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest tubes removed as soon as the drainage fluid turned to serosanguineous.
Number of subjects: 80
Study 12809395 — intervention group
Group type: COMPARATOR
Intervention: Chest tubes removed at the second postoperative day when drainage output declined to less than 50 mL in a five-hour period.
Number of subjects: 80
Study 12809395 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain hematocrit to blood hematocrit ratio before drain removal.
Number of subjects: 80
Study 10574299 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-specific support
Number of subjects: 0
Study 10574299 — intervention group
Group type: EXPERIMENTAL
Intervention: General social support
Number of subjects: 0
Study 10574299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both general and alcohol-specific support
Number of subjects: 0
Study 8919517 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby wipes with pH 2.8
Number of subjects: 302
Study 8919517 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby wipes with pH 5.5
Number of subjects: 302
Study 8919517 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby wipes with intermediate pH 3.7
Number of subjects: 302
Study 8919517 — intervention group
Group type: COMPARATOR
Intervention: Soap and water (control)
Number of subjects: 302
Study 1365219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive information (rational and accurate explanation)
Number of subjects: 0
Study 1365219 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching a monitor (regardless of content)
Number of subjects: 0
Study 1365219 — intervention group
Group type: COMPARATOR
Intervention: Accurate monitoring of hand temperature
Number of subjects: 0
Study 1365219 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation and self-efficacy
Number of subjects: 0
Study 1365219 — intervention group
Group type: EXPERIMENTAL
Intervention: Self prediction of anticipated performance
Number of subjects: 0
Study 7038244 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeromammogram interpretation by radiologists
Number of subjects: 100
Study 7038244 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of cancer
Number of subjects: 100
Study 7038244 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of benign abnormalities
Number of subjects: 100
Study 7038244 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of normality
Number of subjects: 100
Study 7038244 — intervention group
Group type: EXPERIMENTAL
Intervention: Known cancers identification
Number of subjects: 100
Study 31907007 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) of infliximab
Number of subjects: 850
Study 31907007 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with infliximab without knowledge of drug levels or ADAb status
Number of subjects: 850
Study 31432589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral indentation angle
Number of subjects: 100
Study 31432589 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral indentation depth
Number of subjects: 100
Study 31432589 — intervention group
Group type: EXPERIMENTAL
Intervention: T-angle
Number of subjects: 100
Study 28745674 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM gene mutations (CCM1, CCM2, CCM3) identified through blood sample analysis and whole genome sequencing.
Number of subjects: 73
Study 28745674 — intervention group
Group type: EXPERIMENTAL
Intervention: CCM3 mutations
Number of subjects: 73
Study 28745674 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with mutations
Number of subjects: 73
Study 28745674 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial CCMs
Number of subjects: 73
Study 25982006 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT
Number of subjects: 73
Study 25982006 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 73
Study 23770919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection with 400 μg cobalamin
Number of subjects: 107
Study 23770919 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 107
Study 21386706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment with amlodipine/valsartan (10/320 mg)
Number of subjects: 728
Study 21386706 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate treatment with amlodipine/valsartan (5/160 mg)
Number of subjects: 728
Study 21386706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 728
Study 21386706 — intervention group
Group type: COMPARATOR
Intervention: Moderate treatment
Number of subjects: 728
Study 19393782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensation seeking
Number of subjects: 1587
Study 19393782 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy episodic drinking, living off-campus, going to bars
Number of subjects: 1587
Study 17921831 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5-50 mg/day for 3 months)
Number of subjects: 98
Study 17921831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 15156996 — intervention group
Group type: EXPERIMENTAL
Intervention: IN‐BP (intranasal vaccine without canine‐adenovirus type 2)
Number of subjects: 972
Study 15156996 — intervention group
Group type: EXPERIMENTAL
Intervention: IN‐BPA (intranasal vaccine with canine‐adenovirus type 2)
Number of subjects: 972
Study 15156996 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 972
Study 15156996 — intervention group
Group type: EXPERIMENTAL
Intervention: IN‐BP
Number of subjects: 972
Study 15156996 — intervention group
Group type: EXPERIMENTAL
Intervention: IN‐BPA
Number of subjects: 972
Study 15156996 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine groups
Number of subjects: 972
Study 15156996 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 972
Study 12490862 — intervention group
Group type: EXPERIMENTAL
Intervention: OC 3 g per day
Number of subjects: 79
Study 12490862 — intervention group
Group type: EXPERIMENTAL
Intervention: OC 3 g + VD 1 mg per day
Number of subjects: 79
Study 12490862 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group A)
Number of subjects: 79
Study 10321142 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction
Number of subjects: 0
Study 10321142 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-extraction
Number of subjects: 0
Study 10321142 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontics
Number of subjects: 0
Study 10321142 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 10321142 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed treatments
Number of subjects: 0
Study 10321142 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional treatments
Number of subjects: 0
Study 7840077 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diets (VLEDs)
Number of subjects: 13
Study 7840077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-glucose-tolerance test (OGTT) on day 14
Number of subjects: 13
Study 7840077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-sucrose-tolerance test (OSTT) on day 14
Number of subjects: 13
Study 2239174 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (Claforan)
Number of subjects: 38
Study 2239174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study 20656 — intervention group
Group type: EXPERIMENTAL
Intervention: Benorylate tablets (4.5 g daily dosage)
Number of subjects: 20
Study 20656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30115499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 18
Study 30115499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 28355317 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical music 'Spring' from The Four Seasons by Vivaldi
Number of subjects: 40
Study 26193987 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity-fed infusion (GFI)
Number of subjects: 25
Study 26193987 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion pump (IP)
Number of subjects: 25
Study 26193987 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity-fed infusion with post-administration rinsing (PAR)
Number of subjects: 25
Study 26193987 — intervention group
Group type: COMPARATOR
Intervention: Control group (GFI and IP)
Number of subjects: 25
Study 23914761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fearful face presentation
Number of subjects: 0
Study 23914761 — intervention group
Group type: COMPARATOR
Intervention: Neutral face presentation
Number of subjects: 0
Study 21862934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of plasmapheresis and immunosuppression
Number of subjects: 221
Study 21862934 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids and cytotoxic agents
Number of subjects: 221
Study 21862934 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids alone
Number of subjects: 221
Study 21862934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of plasmapheresis plus corticosteroids and cyclophosphamide
Number of subjects: 221
Study 21862934 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 221
Study 19251134 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK with iris registration (LASIK+IR group)
Number of subjects: 3
Study 19251134 — intervention group
Group type: COMPARATOR
Intervention: Conventional LASIK and manual marking
Number of subjects: 3
Study 19251134 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-guided LASIK and manual marking
Number of subjects: 3
Study 19251134 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK+IR group
Number of subjects: 3
Study 17320090 — intervention group
Group type: EXPERIMENTAL
Intervention: Chokeberry flavonoid extract (3 x 85 mg/day)
Number of subjects: 44
Study 17320090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 15025841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran swallowed whole
Number of subjects: 40
Study 15025841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran crushed and mixed with applesauce
Number of subjects: 40
Study 15025841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ximelagatran dissolved in water and administered via nasogastric tube
Number of subjects: 40
Study 12575392 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant roasted licorice decoction (RRLD) plus low-dose glucocorticoids (GC)
Number of subjects: 43
Study 12575392 — intervention group
Group type: COMPARATOR
Intervention: Normal dosage of glucocorticoids (GC)
Number of subjects: 43
Study 9490238 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Q-wave infarction
Number of subjects: 2046
Study 7874375 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 5 mg + hydrochlorothiazide 6.25 mg
Number of subjects: 18
Study 7874375 — intervention group
Group type: EXPERIMENTAL
Intervention: benazepril 10 mg + hydrochlorothiazide 12.5 mg
Number of subjects: 18
Study 7874375 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 3044673 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexopal (4 g/day)
Number of subjects: 23
Study 3044673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31944491 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 84
Study 31944491 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 84
Study 31675993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 208
Study 31675993 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification based on methylation status (U methylated, C unmethylated)
Number of subjects: 208
Study 31675993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 27500487 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental protective underwear
Number of subjects: 122
Study 27500487 — intervention group
Group type: COMPARATOR
Intervention: Marketed reference protective underwear
Number of subjects: 122
Study 25439510 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS application
Number of subjects: 20
Study 25439510 — intervention group
Group type: EXPERIMENTAL
Intervention: LMT application
Number of subjects: 20
Study 22581292 — intervention group
Group type: COMPARATOR
Intervention: 2×/week balance and tone group (BT)
Number of subjects: 147
Study 22581292 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×/week resistance training (RT1)
Number of subjects: 147
Study 22581292 — intervention group
Group type: EXPERIMENTAL
Intervention: 2×/week resistance training (RT2)
Number of subjects: 147
Study 21745726 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to the left dorsolateral prefrontal cortex, administered for 20 min at an intensity of 2.0 mA during 150 trials of a probabilistic association learning test.
Number of subjects: 20
Study 21745726 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control condition).
Number of subjects: 20
Study 19187822 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 243
Study 19187822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 243
Study 17041847 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (20,000 IU for <12 months; 45,000 IU for >=12 months) every 2 months
Number of subjects: 188
Study 17041847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 12742839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 0.025% ophthalmic solution
Number of subjects: 89
Study 12742839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 11033673 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma education program provided by school nurses, including a comprehensive package of current asthma information and the Open Airways for Schools program.
Number of subjects: 0
Study 8658299 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate induction of labour
Number of subjects: 70
Study 8658299 — intervention group
Group type: COMPARATOR
Intervention: Delayed induction of labour
Number of subjects: 70
Study 1468429 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg loracarbef in fasting state
Number of subjects: 12
Study 1468429 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg loracarbef following a standard breakfast
Number of subjects: 12
Study 1468429 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg loracarbef with 200 mg acetylcysteine
Number of subjects: 12
Study 6385931 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% topical indomethacin
Number of subjects: 283
Study 6385931 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% topical dexamethasone sodium phosphate
Number of subjects: 283